tiprankstipranks
NervGen Pharma (NGENF)
OTHER OTC:NGENF

NervGen Pharma (NGENF) Stock Price & Analysis

34 Followers

NGENF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.10 - $2.99
Previous Close$1.67
Volume397.73K
Average Volume (3M)80.50K
Market Cap
$98.90M
Enterprise Value$88.21M
Total Cash (Recent Filing)C$14.79M
Total Debt (Recent Filing)C$219.24K
Price to Earnings (P/E)-6.8
Beta0.67
May 01, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding59,830,899
10 Day Avg. Volume110,843
30 Day Avg. Volume80,503
Standard Deviation0.21
R-Squared0.17
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)29.57
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-23.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

NervGen Pharma News

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

9.10%0.00%<0.01%90.90%
<0.01% Other Institutional Investors
90.90% Public Companies and
Individual Investors

NGENF FAQ

What was NervGen Pharma’s price range in the past 12 months?
NervGen Pharma lowest stock price was $1.10 and its highest was $2.99 in the past 12 months.
    What is NervGen Pharma’s market cap?
    Currently, no data Available
    When is NervGen Pharma’s upcoming earnings report date?
    NervGen Pharma’s upcoming earnings report date is May 01, 2024 which is in 34 days.
      How were NervGen Pharma’s earnings last quarter?
      NervGen Pharma released its earnings results on Nov 09, 2023. The company reported -$0.051 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.051.
        Is NervGen Pharma overvalued?
        According to Wall Street analysts NervGen Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does NervGen Pharma pay dividends?
          NervGen Pharma does not currently pay dividends.
          What is NervGen Pharma’s EPS estimate?
          NervGen Pharma’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does NervGen Pharma have?
          NervGen Pharma has 59,506,397 shares outstanding.
            What happened to NervGen Pharma’s price movement after its last earnings report?
            NervGen Pharma reported an EPS of -$0.051 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.451%.
              Which hedge fund is a major shareholder of NervGen Pharma?
              Currently, no hedge funds are holding shares in NGENF
              ---

              NervGen Pharma Stock Smart Score

              Company Description

              NervGen Pharma

              NervGen Pharma Corp is a regenerative medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, has placed ahead for both spinal cord injury and multiple sclerosis. The company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 with an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              NovaBay Pharma
              Onconova Therapeutics
              CytoDyn
              Avenue Therapeutics
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis